 Connection
Matthew Greenhawt to Anti-Allergic Agents
This is a "connection" page, showing publications Matthew Greenhawt has written about Anti-Allergic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.505 |
|
|
|
-
Anagnostou A, Bird JA, Chinthrajah S, Dribin TE, Fleischer DM, Kim E, Nowak-Wegrzyn A, Rachid R, Shaker MS, Shreffler W, Sicherer S, Tam J, Vickery BP, Virkud YV, Wang J, Young M, Greenhawt M. The use and implementation of omalizumab as food allergy treatment: Consensus-based guidance and Work Group Report of the Adverse Reactions to Foods Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2025 Jan; 155(1):62-69.e1.
Score: 0.903
-
Shaker M, Anagnostou A, Abrams EM, Lee M, Conway AE, Hsu Blatman KS, Oppenheimer J, Greenhawt M. The Cost-Effectiveness of Omalizumab for Treatment of Food Allergy. J Allergy Clin Immunol Pract. 2024 Sep; 12(9):2481-2489.e1.
Score: 0.877
-
Casale TB, Fiocchi A, Greenhawt M. A practical guide for implementing omalizumab therapy for food allergy. J Allergy Clin Immunol. 2024 Jun; 153(6):1510-1517.
Score: 0.865
-
Shaker M, Oppenheimer J, Wallace D, Lang DM, Rambasek T, Dykewicz M, Greenhawt M. Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis. J Allergy Clin Immunol Pract. 2020 Jul - Aug; 8(7):2360-2369.e1.
Score: 0.638
-
Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit? Ann Allergy Asthma Immunol. 2025 Jan; 134(1):110-121.
Score: 0.222
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|